scholarly journals COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) in patients with multiple sclerosis: a statement by a working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society

2021 ◽  
Author(s):  
Monika Nojszewska ◽  
Alicja Kalinowska ◽  
Monika Adamczyk-Sowa ◽  
Alina Kułakowska ◽  
Halina Bartosik-Psujek
Keyword(s):  
Multiple Sclerosis ◽  
Working Group ◽  
Neurological Society

scholarly journals Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations

2013 ◽  
Vol 40 (3) ◽  
pp. 307-323 ◽  
Author(s):  
Mark S. Freedman ◽  
Daniel Selchen ◽  
Douglas L. Arnold ◽  
Alexandre Prat ◽  
Brenda Banwell ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Working Group ◽  
Current Approach ◽  
Treatment Optimization ◽  
Disability Status ◽  
Rational Choices ◽  
Medium Level ◽  
Level Of Concern ◽  
High Level ◽  
Practical Recommendations

The Canadian Multiple Sclerosis Working Group (CMSWG) developed practical recommendations in 2004 to assist clinicians in optimizing the use of disease-modifying therapies (DMT) in patients with relapsing multiple sclerosis. The CMSWG convened to review how disease activity is assessed, propose a more current approach for assessing suboptimal response, and to suggest a scheme for switching or escalating treatment. Practical criteria for relapses, Expanded Disability Status Scale (EDSS) progression and MRI were developed to classify the clinical level of concern as Low, Medium and High. The group concluded that a change in treatment may be considered in any RRMS patient if there is a high level of concern in any one domain (relapses, progression or MRI), a medium level of concern in any two domains, or a low level of concern in all three domains. These recommendations for assessing treatment response should assist clinicians in making more rational choices in their management of relapsing MS patients.

scholarly journals Wellness and multiple sclerosis: The National MS Society establishes a Wellness Research Working Group and research priorities

2017 ◽  
Vol 24 (3) ◽  
pp. 262-267 ◽  
Author(s):  
Robert W Motl ◽  
Ellen M Mowry ◽  
Dawn M Ehde ◽  
Nicholas G LaRocca ◽  
Kathy E Smith ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Working Group ◽  
Scientific Evidence ◽  
Research Priorities ◽  
Research Society ◽  
Staff Members ◽  
Emotional Wellness ◽  
Optimal Health ◽  
Research Working Group ◽  
Psychosocial Approaches

Background: People with multiple sclerosis (MS) have identified “wellness” and associated behaviors as a high priority based on “social media listening” undertaken by the National MS Society (i.e. the Society). Objective: The Society recently convened a group that consisted of researchers with experience in MS and wellness-related research, Society staff members, and an individual with MS for developing recommendations regarding a wellness research agenda. Method: The members of the group engaged in focal reviews and discussions involving the state of science within three approaches for promoting wellness in MS, namely diet, exercise, and emotional wellness. Results: That process informed a group-mediated activity for developing and prioritizing research goals for wellness in MS. This served as a background for articulating the mission and objectives of the Society’s Wellness Research Working Group. Conclusion: The primary mission of the Wellness Research Working Group is the provision of scientific evidence supporting the application of lifestyle, behavioral, and psychosocial approaches for promoting optimal health of mind, body, and spirit (i.e. wellness) in people with MS as well as managing the disease and its consequences.

scholarly journals Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations

2020 ◽  
Vol 47 (4) ◽  
pp. 437-455 ◽  
Author(s):  
Mark S. Freedman ◽  
Virginia Devonshire ◽  
Pierre Duquette ◽  
Paul S. Giacomini ◽  
Fabrizio Giuliani ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Working Group ◽  
Response To Therapy ◽  
Treatment Optimization ◽  
Course Of Disease ◽  
Disease Modifying Therapies ◽  
Potential Safety ◽  
Future Potential ◽  
Treatment Sequencing ◽  
Monitoring Response

Abstract:The Canadian Multiple Sclerosis Working Group has updated its treatment optimization recommendations (TORs) on the optimal use of disease-modifying therapies for patients with all forms of multiple sclerosis (MS). Recommendations provide guidance on initiating effective treatment early in the course of disease, monitoring response to therapy, and modifying or switching therapies to optimize disease control. The current TORs also address the treatment of pediatric MS, progressive MS and the identification and treatment of aggressive forms of the disease. Newer therapies offer improved efficacy, but also have potential safety concerns that must be adequately balanced, notably when treatment sequencing is considered. There are added discussions regarding the management of pregnancy, the future potential of biomarkers and consideration as to when it may be prudent to stop therapy. These TORs are meant to be used and interpreted by all neurologists with a special interest in the management of MS.

National Multiple Sclerosis Society Working Group on Neuroimaging for the Medical Advisory Board

1987 ◽  
Vol 29 (2) ◽  
pp. 119-119 ◽  
Author(s):  
Arthur K. Asbury ◽  
Robert M. Herndon ◽  
Henry F. McFarland ◽  
W. Ian McDonald ◽  
William J. McIlroy ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Working Group ◽  
Advisory Board ◽  
National Multiple Sclerosis Society
Sign in / Sign up

Export Citation Format

Share Document